Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice number: 1422 – September 2022

Hydrocortisone (Efmody®) 5 mg, 10 mg, 20 mg modified-release hard capsules

Submission by Diurnal Limited

Recommendation of the All Wales Medicines Strategy Group

Hydrocortisone (Efmody®) is recommended as an option for restricted use within NHS Wales.

Hydrocortisone (Efmody®) is licensed for the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and older and in adults.

Hydrocortisone (Efmody®) is restricted for use as a second-line treatment option in adolescents not adequately controlled on maximum guideline doses of immediate-release hydrocortisone; and as a third-line treatment in adults not adequately controlled on maximum guideline doses of immediate-release hydrocortisone and/or prednisolone.

Hydrocortisone (Efmody®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3017), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.